William Chou
Chief Executive Officer en PASSAGE BIO, INC. .
Fortuna: - $ al 31/03/2024
Perfil
William Chou is currently the President, Chief Executive Officer & Director at Passage Bio, Inc. Prior to his current position, he served as the Chief Executive Officer at Aruvant Sciences, Inc. Dr. Chou completed his undergraduate degree at Princeton University, followed by an MBA from Yale School of Management.
He also holds a doctorate degree from the University of Pittsburgh School of Medicine.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
PASSAGE BIO, INC.
-.--% | 18/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de William Chou
| Empresas | Cargo | Inicio |
|---|---|---|
| PASSAGE BIO, INC. | Chief Executive Officer | 10/10/2022 |
Antiguos cargos conocidos de William Chou.
| Empresas | Cargo | Fin |
|---|---|---|
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Chief Executive Officer | - |
Formación de William Chou.
| Princeton University | Undergraduate Degree |
| Yale School of Management | Masters Business Admin |
| University of Pittsburgh School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| PASSAGE BIO, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- William Chou
